Assessment of Platelet-derived GARP in Atherosclerotic Disease (CAPGAD)

Université Catholique de Louvain

Status: Not yet enrolling

Conditions: Atheroma; Carotid Artery; Atheromatosis

Treatments: Other: Tissue sample and data collection

Study type: Observational

Funder types: Other

Identifiers

NCT07364058

CAPGAD

Details and patient eligibility

About

The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Older than 18 years
• Able to give informed consent
• Undergoing carotid or femoral endarterectomy

Exclusion criteria

• Younger than 18 years
• Pregnant
• Dialysis
• Unable to give informed consent

Trial design

200 participants in 1 patient group

Endarterectomy population

Description:

This group includes patients with significant atherosclerotic burden justifying a surgical intervention of carotid or femoral endarterectomy.

Treatment:

Other: Tissue sample and data collection